A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA

Journal of Thoracic Oncology

Volumn 6, Issue 10, 2011, Pages 1639-1648

  Nakamura, Tomomi ^a   Sueoka Aragane, Naoko ^a   Iwanaga, Kentaro ^a,b   Sato, Akemi ^a   Komiya, Kazutoshi ^a   Abe, Tomonori ^a   Ureshino, Norio ^a,b   Hayashi, Shinichiro ^a   Hosomi, Toshiya ^c   Hirai, Mitsuharu ^c   Sueoka, Eisaburo ^d   Kimura, Shinya ^a  

^a SAGA UNIVERSITY   (Japan)

^b Saga Medical School   (Japan)

^c ARKRAY Healthcare Pvt Ltd   (Japan)

^d SAGA UNIVERSITY HOSPITAL   (Japan)

Author keywords

EGFR TKI; Lung cancer; Monitoring system; Plasma DNA; T790M

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GENOMIC DNA; METHIONINE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA BINDING; FEMALE; FLUORESCENCE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; LUNG ADENOCARCINOMA; MALE; MUTATION BIASED POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; NON INVASIVE PROCEDURE; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 80053014135     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31822956e8     Document Type: Article

References (37)

1. Bach PB, Silvestri GA, Hanger M, et al. Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:69S-77S. (Pubitemid 47502800)
2. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
3. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
4. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
6. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792. (Pubitemid 40271173)
7. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
8. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043. (Pubitemid 46799492)
9. Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006;12:5764-5769. (Pubitemid 44629607)
10. Costa DB, Nguyen KS, Cho BC, et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008;14:7060-7067.
11. Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-2899.
12. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181.
13. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105:2070-2075. (Pubitemid 351439466)
14. Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462:1070-1074.
15. Tanaka F, Yoneda K, Kondo N, et al. Circulating tumour cell as a diagnostic marker in primary lung cancer. Clin Cancer Res 2009;15: 6980-6986.
16. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-377.
17. Riethdorf S, Fritsche H, Müller V, et al. Detection of circulating tumour cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007;13: 920-928. (Pubitemid 46340368)
18. Allard WJ, Matera J, Miller MC, et al. Tumour cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-6904. (Pubitemid 39383039)
19. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450:1235-1239.
20. Chen XQ, Stroun M, Magnenat JL, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 1996;2:1033-1035. (Pubitemid 26306844)
21. Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumour suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70. (Pubitemid 29062958)
22. Sorenson GD. Detection of mutated KRAS2 sequences as tumour markers in plasma/serum of patients with gastrointestinal cancer. Clin Cancer Res 2000;6:2129-2137. (Pubitemid 30399177)
23. Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumour DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001;61:4675-4678. (Pubitemid 32691874)
24. Anker P, Mulcahy H, Stroun M. Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies? Int J Cancer 2003;103:149-152. (Pubitemid 35461505)
25. Kuang Y, Rogers A, Yeap BY, et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009;15:2630-2636.
26. Matsumoto N, Kakihara F, Kimura S, et al. Single nucleotide polymorphism genotyping of CYP2C19 using a new automated system. Anal Biochem 2007;370:121-123. (Pubitemid 47404484)
27. Tanaka R, Kuroda J, Stevenson W, et al. Fully automated and superrapid system for the detection of JAK2V617F mutation. Leuk Res 2008;32:1462-1467.
28. Sobin L, Wittekind CH. TNM Classification of Malignant Tumours, 6th Ed. New York: Wiley-Liss, 2002. Pp. 99-103.
29. Sueoka N, Sato A, Eguchi H, et al. Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients. J Cancer Res Clin Oncol 2007;133:93-102. (Pubitemid 44950241)
30. Uhara M, Matsuda K, Taira C, et al. Simple polymerase chain reaction for the detection of mutations and deletions in the epidermal growth factor receptor gene: applications of this method for the diagnosis of non-small-cell lung cancer. Clin Chim Acta 2009;401:68-72.
31. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28:357-360.
32. Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFRamplified lung cancer. J Clin Invest 2006;116:2695-2706. (Pubitemid 44511633)
33. Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006;66:7854-7858. (Pubitemid 44299146)
34. Godin-Heymann N, Bryant I, Rivera MN, et al. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 2007;67:7319-7326. (Pubitemid 47206561)
35. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-1665. (Pubitemid 34292602)
36. Stroun M, Lyautey J, Lederrey C, et al. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 2001;313:139-142. (Pubitemid 33016703)
37. Umetani N, Kim J, Hiramatsu S, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem 2006;52: 1062-1069. (Pubitemid 43794418)